The report “Immune Checkpoint Therapeutics – Hot Targets & Pipeline Analysis”
gives comprehensive insights on the various Immune Checkpoint modulators being
developed for the treatment of various diseases. The report covers all the
drugs being developed in various phases (Discovery, Preclinical & Clinical
development). The pipeline focuses on novel medicines covering small molecules,
monoclonal antibodies, Recombinant proteins, Bi-specific Ab’s, Antibody drug
conjugates, Cell therapy, Peptides, Oncolytic viruses and Vaccines. The report
also covers hot targets in research for Checkpoint modulators.
Access a Report
Copy @ https://www.wiseguyreports.com/reports/440551/immune-checkpoint-therapeutics-hot-targets-pipeline-analysis
.
This report enables
Pharmaceutical /Biotech companies, Academic institutes, Individual researchers,
Investors, Medical technology companies, Service providers and other associated
stake holders to identify and analyze the available licensing/collaborative
commercial opportunities in the Immune Checkpoints Drug market. The report also
provides strategic insights on medicines that are likely to have an impact on
future Immune Checkpoint treatment space. The report in addition to the
monotherapy covers the pipeline for combination therapies associated only with
checkpoint agents.
In order to
effectively deal various diseases, the immune system needs to be able to
generate an appropriate counter response. However, as a part of the natural
fail–safe mechanism, to limit overactive immune responses that could lead to an
auto-immune disease, there are a number of markers (“immune checkpoint
receptors”) found on both tumor cells and antigen presenting cells (dendritic
cells, macrophages etc.) that can down-regulate or suppress T cells once the
corresponding ligand is bound. Currently, Researchers are challenged to
identify various avenues to prevent T cells from binding these
tolerance-inducing ligands either through antibodies or recombinant forms of
ligand or receptors. So, these T cells remain active and ready to tackle
various diseases. Owing to its high response rate and prolonged overall patient
survival the checkpoint therapeutics are gaining in popularity and have shown
some impressive results in the areas of Oncology, Inflammation, Respiratory,
Autoimmune and Infectious disease.
Purchase a 1-User License Copy
@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=440551
.
Major
Points in Table of Content
REPORT DESCRIPTION
INTRODUCTION
• Emerging role of immunotherapy
• Immune checkpoints
• Emerging role of immunotherapy
• Immune checkpoints
HOT TARGETS
• Immune checkpoints-Types
• Stimulatory checkpoint pathways
• Inhibitory checkpoint pathways
• Targets – Immune checkpoints • Other immune checkpoint targets
• Top companies based on revenue
• Top companies based on Pipeline
MARKET SIZING &
DEALS ANALYSIS
• Market dynamics
• Market sizing
• Immune checkpoint Deals
• Market dynamics
• Market sizing
• Immune checkpoint Deals
PIPELINE ANALYSIS
• Development stage
• Leading players
• Target analysis
• Modalities
• Therapeutic Segmentation
•Oncology immune checkpoint pipeline by indication
SMALL MOLECULES
• Pipeline
• Competitive landscape MONOCLONAL ANTIBODIES
• Pipeline
• Competitive landscape RECOMBINANT FUSION PROTEINS
• Pipeline
• Competitive landscape BISPECIFIC ANTIBODIES
• Pipeline
• Competitive landscape ANTIBODY DRUG CONJUGATES (ADC’s)
• Pipeline
• Competitive landscape
OTHERS
• Pipeline
• Competitive landscape
MAJOR PLAYERS
• Company Profiles
• Overview, Pipeline & Deals
Request
a sample copy @ https://www.wiseguyreports.com/sample_request/440551/immune-checkpoint-therapeutics-hot-targets-pipeline-analysis
.
No comments:
Post a Comment